Comparison tool

Pinealon vs Epithalon side-by-side

Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.

Selected (2/4)

PinealonEpithalon

Share this peptide comparison

Property	Pinealon	Epithalon
Category	Bioregulators	Bioregulators
Also known as	EDR, Glu-Asp-Arg	Epitalon, Epithalone, AGAG
FDA approved	No	No
Clinical status	Available in Russia - Not FDA approved Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved	Investigational; primarily Russian research. Source notes current FDA Category 2 status pending formal reclassification activity in 2026. Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved
What to expect	Brain health, sleep, cognitive aging, neuroprotection	Longevity, telomere support, anti-aging, sleep
How it works	Pinealon/EDR is proposed to act as a short peptide bioregulator with epigenetic effects on gene expression and protein synthesis. The supplied source reports that, in neuronal cell systems and related models, Pinealon reduced oxidative-stress-associated reactive oxygen species, lowered necrotic and apoptotic cell death, and affected ERK 1/2 signaling and cell-cycle timing. These mechanisms are not confirmed in human brain studies in the provided evidence.	Epithalon is proposed to act through telomerase-related biology, with cell-culture reports describing telomerase activity and telomere elongation in human fibroblasts. The source also notes possible effects on melatonin, antioxidant defenses, and gene expression in pineal-hypothalamic pathways. Translation from these observations to meaningful human anti-aging outcomes remains unproven in the supplied evidence.
Typical dosing	10-20 mg daily · Once daily, typically evening	5-10 mg daily for 10-20 days · Once daily in cycles · 10-20 days
Research dosing	10-20 mg daily · 10-30 day courses · Oral or sublingual	5-10 mg daily for 10-20 days · 10-20 day cycles · Subcutaneous or intramuscular injection
Typical duration	10-30 day courses	10-20 day cycles
Administration	Oral or sublingual	Subcutaneous or intramuscular injection
Timing	Evening or before bed With or without food	Before bed With or without food
Evidence level	Preclinical	Clinical Trials
Possible side effects	Generally well tolerated (Source-reported general tolerability statement; no human safety dataset was supplied.) Headache (Listed by the source as a reported side effect.) Nausea (Listed by the source as a reported side effect.) +4 more Dizziness (Listed by the source as a reported side effect.) Vivid dreams (Listed by the source as a reported side effect.) Injection site reactions (Listed by the source, although the main administration evidence says oral or sublingual.) Caution with seizure disorders (Source flags this caution, but the supplied evidence does not quantify risk.)	Generally well-tolerated (Reported in the source, but tolerability evidence is limited by the available research base.) Injection site reactions (Reported as a possible effect with injectable administration.) Mild headache (Source describes this as transient.) +3 more Sleep disturbances (Reported as a possible effect; frequency is not established.) Risk of immunogenicity (Listed as a potential risk rather than a quantified event rate.) Long-term safety not established (The source explicitly notes uncertainty about long-term safety.)
Research summary	The supplied source places Pinealon in a preclinical evidence base centered on Russian peptide-bioregulator research. Reported models include cultured cerebellar granule neurons, neutrophils, and PC12 cells, where Pinealon was associated with lower oxidative-stress ROS accumulation, reduced cell death, increased viability, and proliferative activity. Related EDR work is described in Alzheimer's-type in vitro and in vivo models, and the source notes overlap with Cortexin-related activity. The source also states that randomized human trials, human pharmacokinetic data, and human safety data were not available in the cited evidence.	The supplied research narrative gives greatest weight to laboratory and animal data. It cites a 2003 report by Khavinson and colleagues on telomerase activity and telomere changes in cultured human fibroblasts, plus a 2025 review discussing geroprotective and neuroendocrine research. Animal studies are described as reporting lifespan and tumor-incidence findings. Human evidence is characterized as limited, often small or open-label, and not independently replicated at the scale needed to prove lifespan extension or reliable telomere-length effects in people.
References	PubMed PMC +2 more PMC PubMed	PubMed PubMed +2 more WikipediaEpitalon Springer
Full profile	View Details	View Details

Save this comparison

Keep this research set handy with a free PeptiGuide account.

Save this comparison - free account

Track your peptide journey

Turn research into a private protocol log when you are ready.

Track your peptide journey

Educational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.

Property

Pinealon

Epithalon

Category

Bioregulators

Also known as

EDR, Glu-Asp-Arg

Epitalon, Epithalone, AGAG

FDA approved

Clinical status

Available in Russia - Not FDA approved

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

Investigational; primarily Russian research. Source notes current FDA Category 2 status pending formal reclassification activity in 2026.

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

What to expect

Brain health, sleep, cognitive aging, neuroprotection

Longevity, telomere support, anti-aging, sleep

How it works

Pinealon/EDR is proposed to act as a short peptide bioregulator with epigenetic effects on gene expression and protein synthesis. The supplied source reports that, in neuronal cell systems and related models, Pinealon reduced oxidative-stress-associated reactive oxygen species, lowered necrotic and apoptotic cell death, and affected ERK 1/2 signaling and cell-cycle timing. These mechanisms are not confirmed in human brain studies in the provided evidence.

Epithalon is proposed to act through telomerase-related biology, with cell-culture reports describing telomerase activity and telomere elongation in human fibroblasts. The source also notes possible effects on melatonin, antioxidant defenses, and gene expression in pineal-hypothalamic pathways. Translation from these observations to meaningful human anti-aging outcomes remains unproven in the supplied evidence.

Typical dosing

10-20 mg daily · Once daily, typically evening

5-10 mg daily for 10-20 days · Once daily in cycles · 10-20 days

Research dosing

10-20 mg daily · 10-30 day courses · Oral or sublingual

5-10 mg daily for 10-20 days · 10-20 day cycles · Subcutaneous or intramuscular injection

Typical duration

10-30 day courses

10-20 day cycles

Administration

Oral or sublingual

Subcutaneous or intramuscular injection

Timing

Evening or before bed

With or without food

Before bed

With or without food

Evidence level

Preclinical

Clinical Trials

Possible side effects

Generally well tolerated (Source-reported general tolerability statement; no human safety dataset was supplied.)
Headache (Listed by the source as a reported side effect.)
Nausea (Listed by the source as a reported side effect.)

+4 more

Dizziness (Listed by the source as a reported side effect.)
Vivid dreams (Listed by the source as a reported side effect.)
Injection site reactions (Listed by the source, although the main administration evidence says oral or sublingual.)
Caution with seizure disorders (Source flags this caution, but the supplied evidence does not quantify risk.)

Generally well-tolerated (Reported in the source, but tolerability evidence is limited by the available research base.)
Injection site reactions (Reported as a possible effect with injectable administration.)
Mild headache (Source describes this as transient.)

+3 more

Sleep disturbances (Reported as a possible effect; frequency is not established.)
Risk of immunogenicity (Listed as a potential risk rather than a quantified event rate.)
Long-term safety not established (The source explicitly notes uncertainty about long-term safety.)

Research summary

The supplied source places Pinealon in a preclinical evidence base centered on Russian peptide-bioregulator research. Reported models include cultured cerebellar granule neurons, neutrophils, and PC12 cells, where Pinealon was associated with lower oxidative-stress ROS accumulation, reduced cell death, increased viability, and proliferative activity. Related EDR work is described in Alzheimer's-type in vitro and in vivo models, and the source notes overlap with Cortexin-related activity. The source also states that randomized human trials, human pharmacokinetic data, and human safety data were not available in the cited evidence.

The supplied research narrative gives greatest weight to laboratory and animal data. It cites a 2003 report by Khavinson and colleagues on telomerase activity and telomere changes in cultured human fibroblasts, plus a 2025 review discussing geroprotective and neuroendocrine research. Animal studies are described as reporting lifespan and tumor-incidence findings. Human evidence is characterized as limited, often small or open-label, and not independently replicated at the scale needed to prove lifespan extension or reliable telomere-length effects in people.

References

PubMed PMC

+2 more

PMC PubMed

PubMed PubMed

+2 more

WikipediaEpitalon Springer

Full profile

View Details